Sjogren-Larsson Syndrome

Mendelian MONDO:0010031 Pathograph 27 Show in embeddings browser Mendelian disease

Sjogren-Larsson syndrome (SLS) is a rare autosomal recessive neurocutaneous inborn error of lipid metabolism caused by deficiency of fatty aldehyde dehydrogenase (FALDH), encoded by ALDH3A2 on chromosome 17p11.2. FALDH oxidizes long-chain aliphatic aldehydes derived from fatty alcohols, ether glycerolipids, sphingolipids, and leukotriene B4; its loss causes accumulation of fatty aldehydes and fatty alcohols that disrupt membrane and skin-barrier lipids and myelin. SLS is defined by the classic triad of congenital ichthyosis, spastic diplegia (or tetraplegia), and intellectual disability, with a pathognomonic ophthalmologic finding of glistening white dots (crystalline maculopathy) in the retina, periventricular leukoencephalopathy, severe pruritus, and frequent preterm birth.

Ask OpenScientist

Ask a research question about Sjogren-Larsson Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
10
Pathophys.
2
Histopath.
11
Phenotypes
3
Gaps
27
Pathograph
1
Genes
7
Medical Actions
2
Trials
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE NEUROLOGIC
👪

Inheritance

1
Autosomal recessive HP:0000007
SLS is inherited in an autosomal recessive manner; affected individuals carry biallelic ALDH3A2 pathogenic variants.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:10227616 SUPPORT Human Clinical
"ichthyosis, spastic di- or tetralegia, and mental retardation, with autosomal recessive inheritance"
States the autosomal recessive inheritance of SLS.
?

Discussions and Knowledge Gaps

3
By which mechanism does fatty aldehyde/alcohol accumulation actually produce the cutaneous and neurologic injury of SLS — bulk membrane lipid accumulation, formation of reactive aldehyde Schiff-base adducts with amine-containing lipids/proteins, defective eicosanoid (leukotriene) metabolism, or a combination?
KNOWLEDGE GAP OPEN gap_sls_accumulation_to_symptoms_mechanism
Attached to
pathophysiology#Accumulation of Fatty Aldehydes and Fatty Alcohols pathophysiology#CNS Myelin and Membrane Lipid Disruption
The edges from metabolite accumulation to the skin and CNS phenotypes are modeled as INDIRECT_UNKNOWN_INTERMEDIATES because the proximate injurious mechanism is not established. Authoritative review explicitly frames the pathogenesis as one (or a combination) of three competing hypotheses. Resolving which dominates in skin versus brain would sharpen the mechanism model and guide whether therapy should target lipid accumulation, aldehyde reactivity, or eicosanoid signaling.
Show evidence (1 reference)
PMID:16996289 SUPPORT Other
"The pathogenesis of the cutaneous and neurologic symptoms is thought to result from abnormal lipid accumulation in the membranes of skin and brain; the formation of aldehyde Schiff base adducts with amine-containing lipids or proteins; or defective eicosanoid metabolism."
Directly states the three competing pathogenic hypotheses, defining the knowledge gap.
Does lowering leukotriene B4 (e.g., with the 5-lipoxygenase inhibitor zileuton) modify the neurologic and cognitive disease of SLS, or does it relieve only the LTB4-driven pruritus?
OPEN QUESTION OPEN openq_sls_ltb4_therapy_neurologic_benefit
Attached to
pathophysiology#Leukotriene B4 Accumulation phenotypes#Pruritus
In the open-label zileuton trial, pruritus and general well-being improved but neuropsychological testing did not change over the treatment period, leaving open whether LTB4-directed therapy has any disease-modifying effect on the central nervous system component, or whether the neurologic disease is driven by a distinct (lipid-accumulation/adduct) mechanism unaffected by 5-lipoxygenase inhibition.
Show evidence (1 reference)
PMID:11795678 SUPPORT Human Clinical
"Neuropsychological test results did not change significantly. There was, however, a clinically important trend towards improvement in the speed of information processing."
Zileuton improved pruritus but neuropsychological results showed no significant change (only a non-significant trend), motivating the question of whether LTB4-directed therapy is disease-modifying for the CNS.
Does the Aldh3a2-knockout mouse faithfully model the human SLS leukoencephalopathy — and is its proposed mechanism (a decrease in the myelin lipid 2-hydroxygalactosylceramide) the operative mechanism in humans, where the ether-lipid/plasmalogen model instead dominates?
HUMAN MODEL MISMATCH OPEN model_mismatch_sls_aldh3a2_ko_mouse
Attached to
pathophysiology#Ether-Lipid (Plasmalogen) Metabolism Disruption pathophysiology#CNS Myelin and Membrane Lipid Disruption
The Aldh3a2-KO mouse reproduces several SLS-like neurobehavioral abnormalities and implicates decreased 2-hydroxygalactosylceramide and impaired long-chain-base (sphingolipid) metabolism in neurons. This is model-system evidence whose translational validity is uncertain: the human CNS mechanism remains unestablished and the leading human hypothesis is ether-lipid/plasmalogen disruption of myelin, not the sphingolipid route the mouse foregrounds. Whether the murine mechanism operates in human SLS is the open question.
Show evidence (1 reference)
PMID:30085884 SUPPORT Model Organism
"Aldh3a2 KO mice showed several abnormalities corresponding to SLS symptoms in behavioral tests, including increased paw slips on a balance beam and light-induced anxiety."
The KO mouse recapitulates several SLS-like behavioral abnormalities, providing the model-system evidence whose fidelity to the human CNS mechanism is the subject of this mismatch.
⚙

Pathophysiology

10
ALDH3A2 Loss of Function
Biallelic loss-of-function variants in ALDH3A2 (on 17p11.2) abolish the activity of fatty aldehyde dehydrogenase (FALDH), a microsomal NAD-dependent enzyme. More than 70 pathogenic ALDH3A2 variants have been reported, including missense substitutions, deletions, insertions, and splicing errors.
long-chain fatty aldehyde dehydrogenase (NAD+) activity GO:0050061 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased long-chain fatty aldehyde dehydrogenase (NAD+) activity (GO:0050061). GO:0050061 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Impaired Fatty Aldehyde Oxidation Loss of FALDH removes the enzyme that oxidizes fatty aldehydes.
Show evidence (1 reference)
PMID:8528251 SUPPORT Human Clinical
"SLS patients have a profound deficiency in fatty aldehyde dehydrogenase (FALDH) activity."
Establishes that SLS is caused by profound FALDH deficiency from ALDH3A2 mutations.
Impaired Fatty Aldehyde Oxidation
FALDH normally catalyzes the oxidation of long-chain fatty aldehyde to fatty acid, the aldehyde-oxidizing step of the fatty alcohol cycle. Its loss blocks oxidation of fatty aldehydes arising from fatty alcohols, ether glycerolipids, sphingolipids, and leukotriene B4.
fatty acid metabolic process GO:0006631 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased fatty acid metabolic process (GO:0006631). GO:0006631 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Accumulation of Fatty Aldehydes and Fatty Alcohols Blocked oxidation causes substrate accumulation.
Leukotriene B4 Accumulation FALDH also inactivates leukotriene B4 by oxidizing its omega-aldehyde intermediate; loss of this step allows LTB4 to accumulate.
Show evidence (1 reference)
PMID:16996289 SUPPORT Other
"FALDH oxidizes fatty aldehyde substrates arising from metabolism of fatty alcohols, leukotriene B4, ether glycerolipids and other potential sources such as sphingolipids"
Identifies the FALDH substrates whose oxidation fails, including fatty alcohols, LTB4, ether glycerolipids, and sphingolipids.
Accumulation of Fatty Aldehydes and Fatty Alcohols
Undegraded long-chain fatty aldehydes and fatty alcohols accumulate. Reactive fatty aldehydes can form Schiff-base adducts with amine-containing lipids and proteins, and altered lipids are incorporated into cellular membranes, disrupting membrane integrity in skin, brain, and eye.
aldehyde metabolic process GO:0006081 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal aldehyde metabolic process (GO:0006081). GO:0006081 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Defective Lamellar Body Formation and Secretion Abnormal membrane lipids yield defective epidermal lamellar bodies.
Ether-Lipid (Plasmalogen) Metabolism Disruption Fatty alcohol is the precursor for ether-glycerolipid synthesis; accumulation and altered flux disturb plasmalogen homeostasis.
Fatty Aldehyde Schiff-Base Adduct Formation Reactive fatty aldehydes form covalent Schiff-base adducts.
Retinal Crystalline Lipid Deposition Abnormal lipids deposit in the perifoveal retina.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Deficiency of fatty acid aldehyde dehydrogenase (FALDH) causes an accumulation of fatty alcohols and fatty aldehydes, leading to altered cell-membrane integrity primarily affecting skin, eyes, and the central nervous system."
States that fatty alcohol/aldehyde accumulation alters cell-membrane integrity in skin, eyes, and CNS.
Defective Lamellar Body Formation and Secretion
In the absence of FALDH, keratinocytes of the stratum granulosum produce defective lamellar bodies that are empty or lack their cargo membranes and show impaired exocytosis, so the lipid precursors of the stratum corneum barrier are not properly delivered.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology.
skin epidermis UBERON:0001003 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in skin epidermis (UBERON:0001003). UBERON:0001003 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Epidermal Water-Barrier Disruption Defective lamellar-body delivery yields an abnormal stratum corneum barrier.
Show evidence (1 reference)
PMID:21695018 SUPPORT Other
"In the absence of FALDH, the skin produces lamellar bodies that are empty, lack their surrounding vesicle membranes or contain granular contents rather then the usual cargo membranes."
Documents the defective lamellar bodies underlying the epidermal barrier defect in SLS.
Epidermal Water-Barrier Disruption
The abnormal lipid composition of the stratum corneum multilamellar membranes produces a disrupted epidermal water-permeability barrier, the substrate for the clinical ichthyosis.
establishment of skin barrier GO:0061436 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased establishment of skin barrier (GO:0061436). GO:0061436 is a biological process from the Gene Ontology. ↓ DECREASED
skin epidermis UBERON:0001003 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in skin epidermis (UBERON:0001003). UBERON:0001003 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Ichthyosis A disrupted water barrier produces the clinical ichthyosis.
Show evidence (1 reference)
PMID:21695018 SUPPORT Other
"An abnormal lipid composition of the SC membranes often results in a disrupted water barrier and the clinical appearance of ichthyosis."
Links the abnormal stratum corneum lipid composition to a disrupted water barrier and ichthyosis.
Ether-Lipid (Plasmalogen) Metabolism Disruption
FALDH participates in ether-glycerolipid (plasmalogen) metabolism, for which fatty alcohol is a precursor. Plasmalogens are highly abundant in myelin, so disturbed ether-lipid/plasmalogen homeostasis is the leading proposed route from the metabolic block to the central leukoencephalopathy.
Downstream
CNS Myelin and Membrane Lipid Disruption Disturbed plasmalogen homeostasis impairs myelin membrane lipids.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Plasmalogens are particularly abundant lipids in myelin membrane, comprising 40–50% of the total Phoshatidylethanolamine"
Establishes plasmalogens as a dominant myelin membrane lipid, the basis for the ether-lipid route to leukoencephalopathy.
Fatty Aldehyde Schiff-Base Adduct Formation
Reactive accumulated fatty aldehydes form covalent Schiff-base adducts with amine-containing phospholipids and proteins, proposed as an essential pathogenic mechanism and the rationale for aldehyde-scavenger therapy (reproxalap).
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Since fatty aldehyde adduct formation is an essential pathogenic mechanism in SLS, it is possible theoretically that aldehyde scavengers could be used to scavenge or compete as therapeutic targets for endogenously produced aldehydes."
States fatty-aldehyde adduct formation as an essential pathogenic mechanism and the rationale for aldehyde scavengers.
CNS Myelin and Membrane Lipid Disruption
Abnormal accumulation of fatty alcohols and aldehydes disrupts myelin and neural membrane lipids, producing a periventricular-predominant leukoencephalopathy with a characteristic abnormal lipid peak at 1.3 ppm on cerebral MR spectroscopy.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
white matter UBERON:0002316 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in white matter (UBERON:0002316). UBERON:0002316 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Leukoencephalopathy Myelin lipid disruption produces periventricular leukoencephalopathy.
Spastic Diplegia White-matter (corticospinal) involvement produces spasticity.
Intellectual Disability Cerebral involvement impairs cognitive development.
Seizures Cortical/white-matter involvement predisposes to seizures.
Dysarthria Pseudobulbar involvement produces dysarthric speech.
Contractures Chronic spasticity leads to fixed joint contractures.
Show evidence (1 reference)
PMID:10227616 SUPPORT Human Clinical
"MRI and 1H MRS findings suggest an accumulation of long-chain fatty alcohol intermediates, resulting in retarded myelination and dysmyelination"
MRI/MR-spectroscopy directly links accumulated long-chain fatty alcohol intermediates to retarded myelination and dysmyelination, supporting this node's myelin-lipid-disruption mechanism.
Leukotriene B4 Accumulation
FALDH normally oxidizes the omega-aldehyde intermediate in leukotriene B4 degradation; its loss makes LTB4 degradation defective, so this potent pruritogenic eicosanoid accumulates. This node is the target of the 5-lipoxygenase inhibitor zileuton.
Downstream
Pruritus Accumulated LTB4, a potent pruritogen, drives severe itch.
Premature Birth Elevated leukotriene B4 (reported in amniotic fluid) is hypothesized to contribute to the high rate of preterm birth; the causal link is not established.
Show evidence (1 reference)
PMID:11795678 SUPPORT Human Clinical
"The degradation of leukotriene (LT) B4 is one of the defective metabolic routes in SLS."
Establishes defective LTB4 degradation as a metabolic consequence of FALDH deficiency in SLS.
Retinal Crystalline Lipid Deposition
Abnormal lipid accumulation in the perifoveal retina produces glistening white dots (a crystalline maculopathy / juvenile macular dystrophy), a pathognomonic ophthalmologic feature of SLS.
retina UBERON:0000966 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in retina (UBERON:0000966). UBERON:0000966 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Macular Crystals Perifoveal lipid deposits appear as glistening white dots.
Photophobia Macular involvement is associated with photophobia.
Show evidence (1 reference)
PMID:31512987 SUPPORT Other
"characterized by a distinctive crystalline maculopathy, congenital ichthyosis, spasticity and intellectual disability"
Identifies the distinctive crystalline maculopathy as a defining ocular feature of SLS.
✶

Histopathology

2
Epidermal Hyperkeratosis with Defective Lamellar Bodies
Skin biopsy shows pronounced hyperkeratosis, papillomatosis, and acanthosis; ultrastructurally there is global disruption of lamellar body formation and secretion, the direct observational correlate of the epidermal barrier defect.
Show evidence (2 references)
PMID:32021380 SUPPORT Other
"pronounced hyperkeratosis, papillomatosis and acanthosis"
Documents the light-microscopic skin findings in SLS.
PMID:32021380 SUPPORT Other
"global disruption of lamellar body formation and secretion"
Documents the ultrastructural lamellar-body disruption anchoring the epidermal-barrier node.
Cortical, Basal Ganglia, and Cerebellar Neuronal Degeneration
Neuropathology shows degeneration of neurons in the cerebral cortex and basal ganglia, with Purkinje cell loss in the cerebellum, alongside white matter demyelination.
Show evidence (2 references)
PMID:32021380 SUPPORT Other
"degeneration of the neurons in the cortex and basal ganglia"
Documents cortical and basal ganglia neuronal degeneration in SLS.
PMID:32021380 SUPPORT Other
"Purkinje cell loss and small foci of atrophy are noted in the cerebellum"
Documents cerebellar Purkinje cell loss in SLS.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Sjogren-Larsson Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Eye 1
Photophobia HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31512987 SUPPORT Other
"Photophobia is common."
Documents photophobia as a common ocular feature of SLS.
Integument 2
Ichthyosis VERY_FREQUENT HP:0008064 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ichthyosis (HP:0008064), qualified as congenital onset. HP:0008064 is a phenotype from the Human Phenotype Ontology.
Onset: CONGENITAL
Show evidence (1 reference)
PMID:16996289 SUPPORT Other
"Affected patients display ichthyosis, mental retardation and spastic diplegia."
Ichthyosis is one of the three defining features of SLS.
Pruritus FREQUENT HP:0000989 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pruritus (HP:0000989). HP:0000989 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11795678 SUPPORT Human Clinical
"Patients also suffer from severe pruritus."
Documents severe pruritus as a feature of SLS.
Musculoskeletal 1
Contractures FREQUENT Flexion contracture HP:0001371 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flexion contracture (HP:0001371). HP:0001371 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Contractures are common."
Documents contractures as a common musculoskeletal feature of SLS.
Nervous System 4
Intellectual Disability VERY_FREQUENT HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16996289 SUPPORT Other
"Affected patients display ichthyosis, mental retardation and spastic diplegia."
Intellectual disability (mental retardation) is one of the three defining features of SLS.
Leukoencephalopathy HP:0002352 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Leukoencephalopathy (HP:0002352). HP:0002352 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Magnetic resonance imaging of the brain demonstrates leukoencephalopathy predominant in the periventricular region."
Documents the periventricular leukoencephalopathy characteristic of SLS.
Seizures FREQUENT HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Isolated or infrequent seizures occur in 35–40% of the patients."
Quantifies seizure occurrence at 35-40%, supporting a FREQUENT band.
Dysarthria FREQUENT HP:0001260 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysarthria (HP:0001260). HP:0001260 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Speech difficulties are common in patients with SLS. Usually, the dysarthria is pseudo bulbar type and mild to moderate in severity."
Documents common pseudobulbar dysarthria in SLS.
Prenatal and Birth 1
Premature Birth FREQUENT HP:0001622 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Premature birth (HP:0001622). HP:0001622 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Preterm birth is common."
Documents preterm birth as a common feature of SLS.
Other 2
Spastic Diplegia VERY_FREQUENT HP:0001264 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spastic diplegia (HP:0001264). HP:0001264 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16996289 SUPPORT Other
"Affected patients display ichthyosis, mental retardation and spastic diplegia."
Spastic diplegia is one of the three defining features of SLS.
Macular Crystals HP:0030501 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macular crystals (glistening white dots), annotated with Macular crystals (HP:0030501). HP:0030501 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
""Glistening white dots" in the retina is a pathognomic clinical feature."
Documents the pathognomonic glistening white retinal dots (crystalline maculopathy).
🧬

Genetic Associations

1
ALDH3A2
Gene: ALDH3A2 hgnc:403 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ALDH3A2 (hgnc:403). hgnc:403 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (3 references)
PMID:8528251 SUPPORT Human Clinical
"We have now cloned the human FALDH cDNA and show that it maps to the SLS locus on chromosome 17p11.2."
Identifies ALDH3A2/FALDH at 17p11.2 as the SLS gene.
PMID:32021380 SUPPORT Other
"943C>T (p. Pro315Ser) mutation is common in Swedish patients"
Names the recurrent Swedish founder allele c.943C>T (p.Pro315Ser).
PMID:32021380 SUPPORT Other
"1297_1298delGA (p. Glu433Argfs*3) allele in European patients"
Names the recurrent European founder allele c.1297_1298delGA (p.Glu433Argfs*3).
💊

Medical Actions

7
Zileuton
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: zileuton CHEBI:10112 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses zileuton (CHEBI:10112). CHEBI:10112 is a therapeutic agent from Chemical Entities of Biological Interest.
Zileuton, a 5-lipoxygenase inhibitor, reduces synthesis of leukotriene B4 and cysteinyl leukotrienes, targeting the LTB4 arm of the metabolic defect. An open-label trial reported improved pruritus and general well-being; a subsequent double-blind placebo-controlled crossover study did not confirm a pruritus benefit, so the evidence is mixed.
Mechanism Target:
INHIBITS Leukotriene B4 Accumulation — Zileuton inhibits 5-lipoxygenase, lowering leukotriene B4 synthesis and thereby the accumulated pruritogenic LTB4 that this node represents.
Target Phenotypes: Pruritus HP:0000989 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Pruritus (HP:0000989). HP:0000989 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:11795678 SUPPORT Human Clinical
"Favourable effects were found on pruritus score (P = 0.006), general well-being, and background activity of electroencephalographic studies."
An open-label trial of zileuton showed improvement in pruritus and general well-being in SLS patients.
PMID:32021380 SUPPORT Other
"could not be replicated in a double-blind cross over study involving 10 SLS patients"
A subsequent double-blind crossover RCT did not replicate the open-label pruritus benefit, so the evidence for zileuton is mixed.
Topical Skin-Barrier Care
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Symptomatic skin management to restore the epidermal water barrier includes moisturizing lotions, keratolytic removal of excess scale, topical retinoids, and urea-containing creams.
Target Phenotypes: Ichthyosis HP:0008064 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Ichthyosis (HP:0008064). HP:0008064 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"moisturizing lotions, removing excess scales with keratolytic agents or using retinoids"
Describes topical measures used to manage the ichthyosis/skin-barrier defect.
Medium-Chain Triglyceride Dietary Intervention
Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
A fat-modified diet supplemented with medium-chain triglycerides (which bypass long-chain fatty alcohol synthesis) has been used as a disease-directed dietary approach.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"diet supplemented by medium chain triglycerides"
Describes the medium-chain-triglyceride dietary approach used in SLS.
Systemic Acitretin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: acitretin CHEBI:50172 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses acitretin (CHEBI:50172). CHEBI:50172 is a therapeutic agent from Chemical Entities of Biological Interest.
Oral acitretin, a systemic retinoid, produces marked improvement in the cutaneous (ichthyosis) symptoms of SLS and is generally well tolerated.
Target Phenotypes: Ichthyosis HP:0008064 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Ichthyosis (HP:0008064). HP:0008064 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Short-acting retinoid acitretin is effective in patients with SLS."
Systemic acitretin is reported effective for the cutaneous disease in SLS.
Baclofen for Spasticity
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: baclofen CHEBI:2972 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses baclofen (CHEBI:2972). CHEBI:2972 is a therapeutic agent from Chemical Entities of Biological Interest.
Oral or intrathecal baclofen is used to manage the spasticity of SLS; intrathecal baclofen has been tried with favorable response.
Target Phenotypes: Spastic diplegia HP:0001264 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Spastic diplegia (HP:0001264). HP:0001264 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Intrathecal baclofen therapy has been tried in patients with SLS"
Documents baclofen (including intrathecal) for spasticity management in SLS.
Physiotherapy
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Early physiotherapy, together with orthopedic procedures (tendon lengthening, adductor release, dorsal rhizotomy), is used to manage spasticity and preserve mobility.
Target Phenotypes: Spastic diplegia HP:0001264 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Spastic diplegia (HP:0001264). HP:0001264 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"benefitted by early physiotherapy"
Documents early physiotherapy as part of spasticity/mobility management.
Reproxalap (Aldehyde Scavenger)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Reproxalap (ADX-102), a reactive-aldehyde scavenger, is an investigational disease-directed topical therapy designed to sequester the accumulated fatty aldehydes that form pathogenic Schiff-base adducts; evaluated in a Phase 3 trial (NCT03445650).
Mechanism Target:
INHIBITS Fatty Aldehyde Schiff-Base Adduct Formation — Reproxalap scavenges reactive fatty aldehydes, reducing the covalent Schiff-base adduct formation this node represents.
Target Phenotypes: Ichthyosis HP:0008064 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Ichthyosis (HP:0008064). HP:0008064 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"it is possible theoretically that aldehyde scavengers could be used to scavenge or compete as therapeutic targets for endogenously produced aldehydes."
States the aldehyde-scavenger therapeutic rationale that reproxalap implements.
🔬

Biochemical Markers

2
Elevated Long-Chain Fatty Alcohols
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"accumulating to 25 fold more fatty alcohols in SLS keratinocytes"
Quantifies the ~25-fold fatty alcohol accumulation in SLS keratinocytes.
Profound Urinary Leukotriene B4 Excretion
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"SLS is the only condition described with profound urinary excretion of LTB4"
Documents the SLS-specific profound urinary LTB4 excretion.
🔬

Diagnosis

3
FALDH Enzyme Assay and ALDH3A2 Molecular Testing
Diagnosis is established by demonstrating deficient FALDH enzyme activity in cultured fibroblasts and/or by identifying biallelic ALDH3A2 pathogenic variants on molecular genetic testing, in a proband with the characteristic phenotype.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Diagnosis requires measurement of FALDH activity in cultured fibroblasts or mutation analysis of the FALDH gene."
States the two confirmatory diagnostic routes (FALDH enzyme assay; ALDH3A2 molecular testing).
Cerebral MR Spectroscopy
Cerebral proton MR spectroscopy shows a characteristic abnormal lipid peak at 1.3 ppm (with a smaller peak at 0.9 ppm), a near-diagnostic imaging biomarker of SLS.
magnetic resonance spectroscopy NCIT:C16810 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"Cerebral MR spectroscopy reveals a characteristic abnormal lipid peak at 1.3ppm and a small peak at 0.9ppm."
Documents the characteristic 1.3 ppm MR-spectroscopy lipid peak used as an imaging biomarker.
Urinary Leukotriene B4 Measurement
SLS patients uniquely show profound urinary excretion of leukotriene B4 and omega-hydroxy-LTB4 with absent omega-carboxy-LTB4, a non-invasive biochemical marker reflecting the FALDH block in LTB4 degradation.
clinical chemistry assessment NCIT:C47868 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"SLS is the only condition described with profound urinary excretion of LTB4"
Documents the SLS-specific profound urinary LTB4 excretion usable as a biochemical marker.
📊

Prevalence

1
Sweden
Point Prevalence 0.4 per 100,000 1–9 per 1,000,000
SLS is ultra-rare and reported worldwide; the best-characterized estimate is ~1 in 250,000 in Sweden (where it was first described), with a regional founder cluster of much higher prevalence in Vasterbotten, northern Sweden.
Show evidence (1 reference)
PMID:32021380 SUPPORT Other
"The estimated prevalence in Sweden where the largest number of patients have been identified is about one in 250,000."
Provides the Swedish prevalence estimate of ~1 in 250,000.
🔬

Clinical Trials

2
NCT03445650 PHASE_III COMPLETED
Phase 3 randomized, double-blind, vehicle-controlled trial of ADX-102 1% topical dermal cream (reproxalap), a reactive-aldehyde scavenger, in subjects with Sjogren-Larsson syndrome — a disease-directed approach targeting the accumulated fatty aldehydes.
Target Phenotypes: Ichthyosis HP:0008064 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Ichthyosis (HP:0008064). HP:0008064 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT03445650 SUPPORT Human Clinical
"A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS)."
A completed Phase 3 trial of the aldehyde-scavenger reproxalap, a disease-directed therapy for SLS.
NCT01971957 COMPLETED
Longitudinal natural-history study of SLS defining the clinical spectrum and course and identifying biochemical biomarkers that correlate with phenotype.
Show evidence (1 reference)
clinicaltrials:NCT01971957 SUPPORT Human Clinical
"The purpose of this study is to define the clinical spectrum and natural history of Sjogren-Larsson syndrome, and identify biomarkers that correlate with disease phenotype"
A natural-history/biomarker study of SLS.
{ }

Source YAML

click to show 
name: Sjogren-Larsson Syndrome
creation_date: "2026-07-29T18:10:00Z"
category: Mendelian
disease_term:
  preferred_term: Sjogren-Larsson syndrome
  term:
    id: MONDO:0010031
    label: Sjogren-Larsson syndrome
description: >
  Sjogren-Larsson syndrome (SLS) is a rare autosomal recessive neurocutaneous
  inborn error of lipid metabolism caused by deficiency of fatty aldehyde
  dehydrogenase (FALDH), encoded by ALDH3A2 on chromosome 17p11.2. FALDH oxidizes
  long-chain aliphatic aldehydes derived from fatty alcohols, ether
  glycerolipids, sphingolipids, and leukotriene B4; its loss causes accumulation
  of fatty aldehydes and fatty alcohols that disrupt membrane and skin-barrier
  lipids and myelin. SLS is defined by the classic triad of congenital
  ichthyosis, spastic diplegia (or tetraplegia), and intellectual disability,
  with a pathognomonic ophthalmologic finding of glistening white dots
  (crystalline maculopathy) in the retina, periventricular leukoencephalopathy,
  severe pruritus, and frequent preterm birth.
parents:
- Mendelian disease
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:32021380
      reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Sjogren Larsson syndrome (SLS) is a rare autosomal recessive inborn error of lipid metabolism due to mutations in the ALDH3A2 that result in a deficiency of fatty aldehyde dehydrogenase (FALDH)."
      explanation: Characterizes SLS as an autosomal recessive inborn error of metabolism, supporting the Mendelian/metabolic Part.
  - classification_value: NEUROLOGIC
pathophysiology:
- name: ALDH3A2 Loss of Function
  biological_scale: MOLECULAR
  description: >
    Biallelic loss-of-function variants in ALDH3A2 (on 17p11.2) abolish the
    activity of fatty aldehyde dehydrogenase (FALDH), a microsomal NAD-dependent
    enzyme. More than 70 pathogenic ALDH3A2 variants have been reported,
    including missense substitutions, deletions, insertions, and splicing errors.
  molecular_functions:
  - preferred_term: long-chain fatty aldehyde dehydrogenase (NAD+) activity
    term:
      id: GO:0050061
      label: long-chain fatty aldehyde dehydrogenase (NAD+) activity
    modifier: DECREASED
  downstream:
  - target: Impaired Fatty Aldehyde Oxidation
    description: Loss of FALDH removes the enzyme that oxidizes fatty aldehydes.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:8528251
    reference_title: "Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SLS patients have a profound deficiency in fatty aldehyde dehydrogenase (FALDH) activity."
    explanation: Establishes that SLS is caused by profound FALDH deficiency from ALDH3A2 mutations.
- name: Impaired Fatty Aldehyde Oxidation
  biological_scale: MOLECULAR
  description: >
    FALDH normally catalyzes the oxidation of long-chain fatty aldehyde to fatty
    acid, the aldehyde-oxidizing step of the fatty alcohol cycle. Its loss blocks
    oxidation of fatty aldehydes arising from fatty alcohols, ether
    glycerolipids, sphingolipids, and leukotriene B4.
  biological_processes:
  - preferred_term: fatty acid metabolic process
    term:
      id: GO:0006631
      label: fatty acid metabolic process
    modifier: DECREASED
  downstream:
  - target: Accumulation of Fatty Aldehydes and Fatty Alcohols
    description: Blocked oxidation causes substrate accumulation.
    causal_link_type: DIRECT
  - target: Leukotriene B4 Accumulation
    description: >
      FALDH also inactivates leukotriene B4 by oxidizing its omega-aldehyde
      intermediate; loss of this step allows LTB4 to accumulate.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:16996289
    reference_title: "Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FALDH oxidizes fatty aldehyde substrates arising from metabolism of fatty alcohols, leukotriene B4, ether glycerolipids and other potential sources such as sphingolipids"
    explanation: Identifies the FALDH substrates whose oxidation fails, including fatty alcohols, LTB4, ether glycerolipids, and sphingolipids.
- name: Accumulation of Fatty Aldehydes and Fatty Alcohols
  biological_scale: MOLECULAR
  description: >
    Undegraded long-chain fatty aldehydes and fatty alcohols accumulate. Reactive
    fatty aldehydes can form Schiff-base adducts with amine-containing lipids and
    proteins, and altered lipids are incorporated into cellular membranes,
    disrupting membrane integrity in skin, brain, and eye.
  biological_processes:
  - preferred_term: aldehyde metabolic process
    term:
      id: GO:0006081
      label: aldehyde metabolic process
    modifier: ABNORMAL
  downstream:
  - target: Defective Lamellar Body Formation and Secretion
    description: Abnormal membrane lipids yield defective epidermal lamellar bodies.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Ether-Lipid (Plasmalogen) Metabolism Disruption
    description: >
      Fatty alcohol is the precursor for ether-glycerolipid synthesis;
      accumulation and altered flux disturb plasmalogen homeostasis.
    causal_link_type: DIRECT
  - target: Fatty Aldehyde Schiff-Base Adduct Formation
    description: Reactive fatty aldehydes form covalent Schiff-base adducts.
    causal_link_type: DIRECT
  - target: Retinal Crystalline Lipid Deposition
    description: Abnormal lipids deposit in the perifoveal retina.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Deficiency of fatty acid aldehyde dehydrogenase (FALDH) causes an accumulation of fatty alcohols and fatty aldehydes, leading to altered cell-membrane integrity primarily affecting skin, eyes, and the central nervous system."
    explanation: States that fatty alcohol/aldehyde accumulation alters cell-membrane integrity in skin, eyes, and CNS.
- name: Defective Lamellar Body Formation and Secretion
  conforms_to: "epidermal_cornification_failure#Defective Cornified Envelope Assembly and Lamellar Lipid Delivery"
  biological_scale: CELLULAR
  description: >
    In the absence of FALDH, keratinocytes of the stratum granulosum produce
    defective lamellar bodies that are empty or lack their cargo membranes and
    show impaired exocytosis, so the lipid precursors of the stratum corneum
    barrier are not properly delivered.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: Epidermal Water-Barrier Disruption
    description: Defective lamellar-body delivery yields an abnormal stratum corneum barrier.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21695018
    reference_title: "The role of fatty aldehyde dehydrogenase in epidermal structure and function."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the absence of FALDH, the skin produces lamellar bodies that are empty, lack their surrounding vesicle membranes or contain granular contents rather then the usual cargo membranes."
    explanation: Documents the defective lamellar bodies underlying the epidermal barrier defect in SLS.
- name: Epidermal Water-Barrier Disruption
  conforms_to: "epidermal_cornification_failure#Stratum Corneum Permeability Barrier Failure"
  biological_scale: TISSUE
  description: >
    The abnormal lipid composition of the stratum corneum multilamellar
    membranes produces a disrupted epidermal water-permeability barrier, the
    substrate for the clinical ichthyosis.
  biological_processes:
  - preferred_term: establishment of skin barrier
    term:
      id: GO:0061436
      label: establishment of skin barrier
    modifier: DECREASED
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: Ichthyosis
    description: A disrupted water barrier produces the clinical ichthyosis.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21695018
    reference_title: "The role of fatty aldehyde dehydrogenase in epidermal structure and function."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An abnormal lipid composition of the SC membranes often results in a disrupted water barrier and the clinical appearance of ichthyosis."
    explanation: Links the abnormal stratum corneum lipid composition to a disrupted water barrier and ichthyosis.
- name: Ether-Lipid (Plasmalogen) Metabolism Disruption
  biological_scale: MOLECULAR
  description: >
    FALDH participates in ether-glycerolipid (plasmalogen) metabolism, for which
    fatty alcohol is a precursor. Plasmalogens are highly abundant in myelin, so
    disturbed ether-lipid/plasmalogen homeostasis is the leading proposed route
    from the metabolic block to the central leukoencephalopathy.
  downstream:
  - target: CNS Myelin and Membrane Lipid Disruption
    description: Disturbed plasmalogen homeostasis impairs myelin membrane lipids.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Plasmalogens are particularly abundant lipids in myelin membrane, comprising 40–50% of the total Phoshatidylethanolamine"
    explanation: Establishes plasmalogens as a dominant myelin membrane lipid, the basis for the ether-lipid route to leukoencephalopathy.
- name: Fatty Aldehyde Schiff-Base Adduct Formation
  biological_scale: MOLECULAR
  description: >
    Reactive accumulated fatty aldehydes form covalent Schiff-base adducts with
    amine-containing phospholipids and proteins, proposed as an essential
    pathogenic mechanism and the rationale for aldehyde-scavenger therapy
    (reproxalap).
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Since fatty aldehyde adduct formation is an essential pathogenic mechanism in SLS, it is possible theoretically that aldehyde scavengers could be used to scavenge or compete as therapeutic targets for endogenously produced aldehydes."
    explanation: States fatty-aldehyde adduct formation as an essential pathogenic mechanism and the rationale for aldehyde scavengers.
- name: CNS Myelin and Membrane Lipid Disruption
  biological_scale: TISSUE
  description: >
    Abnormal accumulation of fatty alcohols and aldehydes disrupts myelin and
    neural membrane lipids, producing a periventricular-predominant
    leukoencephalopathy with a characteristic abnormal lipid peak at 1.3 ppm on
    cerebral MR spectroscopy.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  downstream:
  - target: Leukoencephalopathy
    description: Myelin lipid disruption produces periventricular leukoencephalopathy.
    causal_link_type: DIRECT
  - target: Spastic Diplegia
    description: White-matter (corticospinal) involvement produces spasticity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intellectual Disability
    description: Cerebral involvement impairs cognitive development.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizures
    description: Cortical/white-matter involvement predisposes to seizures.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dysarthria
    description: Pseudobulbar involvement produces dysarthric speech.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Contractures
    description: Chronic spasticity leads to fixed joint contractures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - spasticity-driven joint immobility
  evidence:
  - reference: PMID:10227616
    reference_title: "Sjögren-Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI and 1H MRS findings suggest an accumulation of long-chain fatty alcohol intermediates, resulting in retarded myelination and dysmyelination"
    explanation: >-
      MRI/MR-spectroscopy directly links accumulated long-chain fatty alcohol
      intermediates to retarded myelination and dysmyelination, supporting this
      node's myelin-lipid-disruption mechanism.
- name: Leukotriene B4 Accumulation
  biological_scale: MOLECULAR
  description: >
    FALDH normally oxidizes the omega-aldehyde intermediate in leukotriene B4
    degradation; its loss makes LTB4 degradation defective, so this potent
    pruritogenic eicosanoid accumulates. This node is the target of the
    5-lipoxygenase inhibitor zileuton.
  downstream:
  - target: Pruritus
    description: Accumulated LTB4, a potent pruritogen, drives severe itch.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - leukotriene B4-mediated pruritogenic signaling
  - target: Premature Birth
    description: >
      Elevated leukotriene B4 (reported in amniotic fluid) is hypothesized to
      contribute to the high rate of preterm birth; the causal link is not
      established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:11795678
    reference_title: "Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The degradation of leukotriene (LT) B4 is one of the defective metabolic routes in SLS."
    explanation: Establishes defective LTB4 degradation as a metabolic consequence of FALDH deficiency in SLS.
- name: Retinal Crystalline Lipid Deposition
  biological_scale: TISSUE
  description: >
    Abnormal lipid accumulation in the perifoveal retina produces glistening
    white dots (a crystalline maculopathy / juvenile macular dystrophy), a
    pathognomonic ophthalmologic feature of SLS.
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  downstream:
  - target: Macular Crystals
    description: Perifoveal lipid deposits appear as glistening white dots.
    causal_link_type: DIRECT
  - target: Photophobia
    description: Macular involvement is associated with photophobia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:31512987
    reference_title: "Sjögren-Larsson syndrome: a complex metabolic disease with a distinctive ocular phenotype."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "characterized by a distinctive crystalline maculopathy, congenital ichthyosis, spasticity and intellectual disability"
    explanation: Identifies the distinctive crystalline maculopathy as a defining ocular feature of SLS.
phenotypes:
- name: Ichthyosis
  category: Integument
  description: >
    Congenital ichthyosis is present from birth (often with a collodion-like or
    erythrodermic neonatal presentation), a core component of the SLS triad.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
    onset:
      onset_category: CONGENITAL
  evidence:
  - reference: PMID:16996289
    reference_title: "Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Affected patients display ichthyosis, mental retardation and spastic diplegia."
    explanation: Ichthyosis is one of the three defining features of SLS.
- name: Spastic Diplegia
  category: Neurological
  description: >
    Spastic diplegia or tetraplegia develops in infancy/early childhood, a core
    component of the SLS triad; many patients are unable to walk.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Spastic diplegia
    term:
      id: HP:0001264
      label: Spastic diplegia
  evidence:
  - reference: PMID:16996289
    reference_title: "Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Affected patients display ichthyosis, mental retardation and spastic diplegia."
    explanation: Spastic diplegia is one of the three defining features of SLS.
- name: Intellectual Disability
  category: Neurological
  description: >
    Intellectual disability (historically "mental retardation") of variable
    severity is a core component of the SLS triad.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:16996289
    reference_title: "Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Affected patients display ichthyosis, mental retardation and spastic diplegia."
    explanation: Intellectual disability (mental retardation) is one of the three defining features of SLS.
- name: Macular Crystals
  category: Eye
  description: >
    Glistening white dots (perifoveal crystalline maculopathy) in the retina, a
    pathognomonic finding of SLS.
  phenotype_term:
    preferred_term: Macular crystals (glistening white dots)
    term:
      id: HP:0030501
      label: Macular crystals
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "\"Glistening white dots\" in the retina is a pathognomic clinical feature."
    explanation: Documents the pathognomonic glistening white retinal dots (crystalline maculopathy).
- name: Leukoencephalopathy
  category: Neurological
  description: >
    MRI demonstrates a periventricular-predominant leukoencephalopathy, with a
    characteristic abnormal lipid peak on cerebral MR spectroscopy.
  phenotype_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Magnetic resonance imaging of the brain demonstrates leukoencephalopathy predominant in the periventricular region."
    explanation: Documents the periventricular leukoencephalopathy characteristic of SLS.
- name: Pruritus
  category: Integument
  description: >
    Severe, often intractable pruritus is a prominent and distressing feature,
    attributed to accumulation of the pruritogen leukotriene B4.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: PMID:11795678
    reference_title: "Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients also suffer from severe pruritus."
    explanation: Documents severe pruritus as a feature of SLS.
- name: Seizures
  category: Neurological
  description: >
    Isolated or infrequent (usually generalized tonic-clonic) seizures occur in
    a substantial minority of patients.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Isolated or infrequent seizures occur in 35–40% of the patients."
    explanation: Quantifies seizure occurrence at 35-40%, supporting a FREQUENT band.
- name: Contractures
  category: Musculoskeletal
  description: >
    Joint contractures are common and contribute to the mobility limitation
    (many patients become wheelchair-dependent).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Contractures are common."
    explanation: Documents contractures as a common musculoskeletal feature of SLS.
- name: Premature Birth
  category: Constitutional
  description: >
    Preterm birth is common in SLS pregnancies, hypothesized to relate to
    elevated amniotic leukotriene B4.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Premature birth
    term:
      id: HP:0001622
      label: Premature birth
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Preterm birth is common."
    explanation: Documents preterm birth as a common feature of SLS.
- name: Dysarthria
  category: Neurological
  description: >
    Dysarthria, usually of pseudobulbar type and mild to moderate severity, is a
    common speech manifestation.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Speech difficulties are common in patients with SLS. Usually, the dysarthria is pseudo bulbar type and mild to moderate in severity."
    explanation: Documents common pseudobulbar dysarthria in SLS.
- name: Photophobia
  category: Eye
  description: >
    Photophobia is a common ocular symptom, associated with the macular changes.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:31512987
    reference_title: "Sjögren-Larsson syndrome: a complex metabolic disease with a distinctive ocular phenotype."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Photophobia is common."
    explanation: Documents photophobia as a common ocular feature of SLS.
genetic:
- name: ALDH3A2
  gene_term:
    preferred_term: ALDH3A2
    term:
      id: hgnc:403
      label: ALDH3A2
  relationship_type: CAUSATIVE
  notes: >
    Biallelic loss-of-function variants in ALDH3A2 (fatty aldehyde
    dehydrogenase, FALDH; 17p11.2) cause SLS. More than 70 pathogenic variants
    have been reported, including missense, deletions, insertions, and splicing
    errors; most are private, with several founder alleles.
  evidence:
  - reference: PMID:8528251
    reference_title: "Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have now cloned the human FALDH cDNA and show that it maps to the SLS locus on chromosome 17p11.2."
    explanation: Identifies ALDH3A2/FALDH at 17p11.2 as the SLS gene.
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "943C>T (p. Pro315Ser) mutation is common in Swedish patients"
    explanation: Names the recurrent Swedish founder allele c.943C>T (p.Pro315Ser).
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1297_1298delGA (p. Glu433Argfs*3) allele in European patients"
    explanation: Names the recurrent European founder allele c.1297_1298delGA (p.Glu433Argfs*3).
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    SLS is inherited in an autosomal recessive manner; affected individuals
    carry biallelic ALDH3A2 pathogenic variants.
  evidence:
  - reference: PMID:10227616
    reference_title: "Sjögren-Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ichthyosis, spastic di- or tetralegia, and mental retardation, with autosomal recessive inheritance"
    explanation: States the autosomal recessive inheritance of SLS.
biochemical:
- name: Elevated Long-Chain Fatty Alcohols
  notes: >
    Long-chain fatty alcohols accumulate markedly (about 25-fold in SLS
    keratinocytes), the primary biochemical consequence of the impaired
    fatty alcohol:NAD oxidoreductase (fatty alcohol cycle).
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "accumulating to 25 fold more fatty alcohols in SLS keratinocytes"
    explanation: Quantifies the ~25-fold fatty alcohol accumulation in SLS keratinocytes.
- name: Profound Urinary Leukotriene B4 Excretion
  notes: >
    SLS uniquely shows profound urinary excretion of leukotriene B4 (with
    elevated omega-hydroxy-LTB4 and absent omega-carboxy-LTB4), reflecting the
    FALDH block in LTB4 omega-oxidation — a specific, non-invasive marker.
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLS is the only condition described with profound urinary excretion of LTB4"
    explanation: Documents the SLS-specific profound urinary LTB4 excretion.
histopathology:
- name: Epidermal Hyperkeratosis with Defective Lamellar Bodies
  description: >
    Skin biopsy shows pronounced hyperkeratosis, papillomatosis, and acanthosis;
    ultrastructurally there is global disruption of lamellar body formation and
    secretion, the direct observational correlate of the epidermal barrier
    defect.
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "pronounced hyperkeratosis, papillomatosis and acanthosis"
    explanation: Documents the light-microscopic skin findings in SLS.
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "global disruption of lamellar body formation and secretion"
    explanation: Documents the ultrastructural lamellar-body disruption anchoring the epidermal-barrier node.
- name: Cortical, Basal Ganglia, and Cerebellar Neuronal Degeneration
  description: >
    Neuropathology shows degeneration of neurons in the cerebral cortex and
    basal ganglia, with Purkinje cell loss in the cerebellum, alongside white
    matter demyelination.
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "degeneration of the neurons in the cortex and basal ganglia"
    explanation: Documents cortical and basal ganglia neuronal degeneration in SLS.
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Purkinje cell loss and small foci of atrophy are noted in the cerebellum"
    explanation: Documents cerebellar Purkinje cell loss in SLS.
diagnosis:
- name: FALDH Enzyme Assay and ALDH3A2 Molecular Testing
  description: >
    Diagnosis is established by demonstrating deficient FALDH enzyme activity in
    cultured fibroblasts and/or by identifying biallelic ALDH3A2 pathogenic
    variants on molecular genetic testing, in a proband with the characteristic
    phenotype.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Diagnosis requires measurement of FALDH activity in cultured fibroblasts or mutation analysis of the FALDH gene."
    explanation: States the two confirmatory diagnostic routes (FALDH enzyme assay; ALDH3A2 molecular testing).
- name: Cerebral MR Spectroscopy
  description: >
    Cerebral proton MR spectroscopy shows a characteristic abnormal lipid peak
    at 1.3 ppm (with a smaller peak at 0.9 ppm), a near-diagnostic imaging
    biomarker of SLS.
  diagnosis_term:
    preferred_term: magnetic resonance spectroscopy
    term:
      id: NCIT:C16810
      label: Magnetic Resonance Spectroscopy
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cerebral MR spectroscopy reveals a characteristic abnormal lipid peak at 1.3ppm and a small peak at 0.9ppm."
    explanation: Documents the characteristic 1.3 ppm MR-spectroscopy lipid peak used as an imaging biomarker.
- name: Urinary Leukotriene B4 Measurement
  description: >
    SLS patients uniquely show profound urinary excretion of leukotriene B4 and
    omega-hydroxy-LTB4 with absent omega-carboxy-LTB4, a non-invasive
    biochemical marker reflecting the FALDH block in LTB4 degradation.
  diagnosis_term:
    preferred_term: clinical chemistry assessment
    term:
      id: NCIT:C47868
      label: Blood Chemistry Measurement
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLS is the only condition described with profound urinary excretion of LTB4"
    explanation: Documents the SLS-specific profound urinary LTB4 excretion usable as a biochemical marker.
prevalence:
- population: Sweden
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.4
  notes: >-
    SLS is ultra-rare and reported worldwide; the best-characterized estimate is
    ~1 in 250,000 in Sweden (where it was first described), with a regional
    founder cluster of much higher prevalence in Vasterbotten, northern Sweden.
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The estimated prevalence in Sweden where the largest number of patients have been identified is about one in 250,000."
    explanation: Provides the Swedish prevalence estimate of ~1 in 250,000.
treatments:
- name: Zileuton
  description: >
    Zileuton, a 5-lipoxygenase inhibitor, reduces synthesis of leukotriene B4
    and cysteinyl leukotrienes, targeting the LTB4 arm of the metabolic defect.
    An open-label trial reported improved pruritus and general well-being; a
    subsequent double-blind placebo-controlled crossover study did not confirm a
    pruritus benefit, so the evidence is mixed.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: zileuton
      term:
        id: CHEBI:10112
        label: zileuton
  target_phenotypes:
  - preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  target_mechanisms:
  - target: Leukotriene B4 Accumulation
    treatment_effect: INHIBITS
    description: >
      Zileuton inhibits 5-lipoxygenase, lowering leukotriene B4 synthesis and
      thereby the accumulated pruritogenic LTB4 that this node represents.
  evidence:
  - reference: PMID:11795678
    reference_title: "Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Favourable effects were found on pruritus score (P = 0.006), general well-being, and background activity of electroencephalographic studies."
    explanation: An open-label trial of zileuton showed improvement in pruritus and general well-being in SLS patients.
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "could not be replicated in a double-blind cross over study involving 10 SLS patients"
    explanation: >-
      A subsequent double-blind crossover RCT did not replicate the open-label
      pruritus benefit, so the evidence for zileuton is mixed.
- name: Topical Skin-Barrier Care
  description: >
    Symptomatic skin management to restore the epidermal water barrier includes
    moisturizing lotions, keratolytic removal of excess scale, topical retinoids,
    and urea-containing creams.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "moisturizing lotions, removing excess scales with keratolytic agents or using retinoids"
    explanation: Describes topical measures used to manage the ichthyosis/skin-barrier defect.
- name: Medium-Chain Triglyceride Dietary Intervention
  description: >
    A fat-modified diet supplemented with medium-chain triglycerides (which
    bypass long-chain fatty alcohol synthesis) has been used as a
    disease-directed dietary approach.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "diet supplemented by medium chain triglycerides"
    explanation: Describes the medium-chain-triglyceride dietary approach used in SLS.
- name: Systemic Acitretin
  description: >
    Oral acitretin, a systemic retinoid, produces marked improvement in the
    cutaneous (ichthyosis) symptoms of SLS and is generally well tolerated.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acitretin
      term:
        id: CHEBI:50172
        label: acitretin
  target_phenotypes:
  - preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Short-acting retinoid acitretin is effective in patients with SLS."
    explanation: Systemic acitretin is reported effective for the cutaneous disease in SLS.
- name: Baclofen for Spasticity
  description: >
    Oral or intrathecal baclofen is used to manage the spasticity of SLS;
    intrathecal baclofen has been tried with favorable response.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  target_phenotypes:
  - preferred_term: Spastic diplegia
    term:
      id: HP:0001264
      label: Spastic diplegia
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Intrathecal baclofen therapy has been tried in patients with SLS"
    explanation: Documents baclofen (including intrathecal) for spasticity management in SLS.
- name: Physiotherapy
  description: >
    Early physiotherapy, together with orthopedic procedures (tendon lengthening,
    adductor release, dorsal rhizotomy), is used to manage spasticity and
    preserve mobility.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  target_phenotypes:
  - preferred_term: Spastic diplegia
    term:
      id: HP:0001264
      label: Spastic diplegia
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "benefitted by early physiotherapy"
    explanation: Documents early physiotherapy as part of spasticity/mobility management.
- name: Reproxalap (Aldehyde Scavenger)
  description: >
    Reproxalap (ADX-102), a reactive-aldehyde scavenger, is an investigational
    disease-directed topical therapy designed to sequester the accumulated
    fatty aldehydes that form pathogenic Schiff-base adducts; evaluated in a
    Phase 3 trial (NCT03445650).
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Fatty Aldehyde Schiff-Base Adduct Formation
    treatment_effect: INHIBITS
    description: >
      Reproxalap scavenges reactive fatty aldehydes, reducing the covalent
      Schiff-base adduct formation this node represents.
  target_phenotypes:
  - preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: PMID:32021380
    reference_title: "Sjogren-Larsson Syndrome: Mechanisms and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "it is possible theoretically that aldehyde scavengers could be used to scavenge or compete as therapeutic targets for endogenously produced aldehydes."
    explanation: States the aldehyde-scavenger therapeutic rationale that reproxalap implements.
clinical_trials:
- name: NCT03445650
  phase: PHASE_III
  status: COMPLETED
  description: >
    Phase 3 randomized, double-blind, vehicle-controlled trial of ADX-102 1%
    topical dermal cream (reproxalap), a reactive-aldehyde scavenger, in subjects
    with Sjogren-Larsson syndrome — a disease-directed approach targeting the
    accumulated fatty aldehydes.
  target_phenotypes:
  - preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: clinicaltrials:NCT03445650
    reference_title: "A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS)."
    explanation: A completed Phase 3 trial of the aldehyde-scavenger reproxalap, a disease-directed therapy for SLS.
- name: NCT01971957
  status: COMPLETED
  description: >
    Longitudinal natural-history study of SLS defining the clinical spectrum and
    course and identifying biochemical biomarkers that correlate with phenotype.
  evidence:
  - reference: clinicaltrials:NCT01971957
    reference_title: "Sjogren-Larsson Syndrome: A Longitudinal Study of Natural History, Clinical Variation and Evaluation of Biochemical Markers"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to define the clinical spectrum and natural history of Sjogren-Larsson syndrome, and identify biomarkers that correlate with disease phenotype"
    explanation: A natural-history/biomarker study of SLS.
discussions:
- discussion_id: gap_sls_accumulation_to_symptoms_mechanism
  prompt: >-
    By which mechanism does fatty aldehyde/alcohol accumulation actually produce
    the cutaneous and neurologic injury of SLS — bulk membrane lipid
    accumulation, formation of reactive aldehyde Schiff-base adducts with
    amine-containing lipids/proteins, defective eicosanoid (leukotriene)
    metabolism, or a combination?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Accumulation of Fatty Aldehydes and Fatty Alcohols
  - pathophysiology#CNS Myelin and Membrane Lipid Disruption
  rationale: >-
    The edges from metabolite accumulation to the skin and CNS phenotypes are
    modeled as INDIRECT_UNKNOWN_INTERMEDIATES because the proximate injurious
    mechanism is not established. Authoritative review explicitly frames the
    pathogenesis as one (or a combination) of three competing hypotheses.
    Resolving which dominates in skin versus brain would sharpen the mechanism
    model and guide whether therapy should target lipid accumulation, aldehyde
    reactivity, or eicosanoid signaling.
  evidence:
  - reference: PMID:16996289
    reference_title: "Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The pathogenesis of the cutaneous and neurologic symptoms is thought to result from abnormal lipid accumulation in the membranes of skin and brain; the formation of aldehyde Schiff base adducts with amine-containing lipids or proteins; or defective eicosanoid metabolism."
    explanation: Directly states the three competing pathogenic hypotheses, defining the knowledge gap.
- discussion_id: openq_sls_ltb4_therapy_neurologic_benefit
  prompt: >-
    Does lowering leukotriene B4 (e.g., with the 5-lipoxygenase inhibitor
    zileuton) modify the neurologic and cognitive disease of SLS, or does it
    relieve only the LTB4-driven pruritus?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - pathophysiology#Leukotriene B4 Accumulation
  - phenotypes#Pruritus
  rationale: >-
    In the open-label zileuton trial, pruritus and general well-being improved
    but neuropsychological testing did not change over the treatment period,
    leaving open whether LTB4-directed therapy has any disease-modifying effect
    on the central nervous system component, or whether the neurologic disease is
    driven by a distinct (lipid-accumulation/adduct) mechanism unaffected by
    5-lipoxygenase inhibition.
  evidence:
  - reference: PMID:11795678
    reference_title: "Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuropsychological test results did not change significantly. There was, however, a clinically important trend towards improvement in the speed of information processing."
    explanation: Zileuton improved pruritus but neuropsychological results showed no significant change (only a non-significant trend), motivating the question of whether LTB4-directed therapy is disease-modifying for the CNS.
- discussion_id: model_mismatch_sls_aldh3a2_ko_mouse
  prompt: >-
    Does the Aldh3a2-knockout mouse faithfully model the human SLS
    leukoencephalopathy — and is its proposed mechanism (a decrease in the
    myelin lipid 2-hydroxygalactosylceramide) the operative mechanism in humans,
    where the ether-lipid/plasmalogen model instead dominates?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Ether-Lipid (Plasmalogen) Metabolism Disruption
  - pathophysiology#CNS Myelin and Membrane Lipid Disruption
  rationale: >-
    The Aldh3a2-KO mouse reproduces several SLS-like neurobehavioral
    abnormalities and implicates decreased 2-hydroxygalactosylceramide and
    impaired long-chain-base (sphingolipid) metabolism in neurons. This is
    model-system evidence whose translational validity is uncertain: the human
    CNS mechanism remains unestablished and the leading human hypothesis is
    ether-lipid/plasmalogen disruption of myelin, not the sphingolipid route the
    mouse foregrounds. Whether the murine mechanism operates in human SLS is the
    open question.
  evidence:
  - reference: PMID:30085884
    reference_title: "Neural symptoms in a gene knockout mouse model of Sjögren-Larsson syndrome are associated with a decrease in 2-hydroxygalactosylceramide."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Aldh3a2 KO mice showed several abnormalities corresponding to SLS symptoms in behavioral tests, including increased paw slips on a balance beam and light-induced anxiety."
    explanation: >-
      The KO mouse recapitulates several SLS-like behavioral abnormalities,
      providing the model-system evidence whose fidelity to the human CNS
      mechanism is the subject of this mismatch.
datasets: []
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Sjögren-Larsson Syndrome (SLS): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 32 citations 2026-07-29T18:02:54.981774

Sjögren-Larsson Syndrome (SLS): Comprehensive Research Report

1. Disease Information

Overview: Sjögren-Larsson syndrome (SLS) is a rare autosomal recessive neurocutaneous inborn error of lipid metabolism caused by deficiency of fatty aldehyde dehydrogenase (FALDH), encoded by ALDH3A2. It is defined by a classic clinical triad — congenital ichthyosis, spastic diplegia/tetraplegia, and intellectual disability — with a pathognomonic ophthalmologic finding (glistening white retinal dots/juvenile macular dystrophy) and characteristic leukoencephalopathy. First described by Sjögren and Larsson in Swedish patients (1956–1957).

Key identifiers: - OMIM: #270200 (phenotype); gene ALDH3A2 OMIM *609523 (HGNC:403, chromosome 17p11.2) - Orphanet: ORPHA:816 - MONDO: MONDO:0010031; Disease Ontology: DOID:14501 - ICD-10: Q87.1 (congenital malformation syndromes predominantly associated with short stature); ICD-11: 5C52.03 - MeSH: Sjogren-Larsson Syndrome

Source of information: This report draws on aggregated disease-level resources (OMIM, Orphanet, GeneReviews-type reviews, MedLink Neurology) and primary literature (case series, natural history cohorts from the Netherlands and Sweden, and single/multi-patient case reports) rather than raw individual EHR data.

Synonyms: SLS; Fatty aldehyde dehydrogenase deficiency; FALDH deficiency; Ichthyosis–spastic diplegia–oligophrenia syndrome.

2. Etiology

Causal factor: SLS is monogenic — biallelic loss-of-function variants in ALDH3A2 cause deficiency of FALDH (also called fatty alcohol:NAD+ oxidoreductase, FAO), leading to accumulation of long-chain fatty aldehydes and fatty alcohols (Rizzo, PMID: 16996289).

Genetic risk factors: - Homozygous or compound heterozygous ALDH3A2 variants are both necessary and sufficient — no modifier genes with established effect have been reported. - Consanguinity substantially raises risk in outbred populations (case series from consanguineous Arab families reported). - Founder mutations: c.943C>T (p.Pro315Ser) is the most common allele in the Swedish founder population (northern Sweden, Västerbotten); c.1297_1298delGA (p.Glu433Argfs*3) is the most common allele among broader European patients. Both arise from single recurrent haplotypes (Journal of Human Genetics, 2019, PMID for founder-effect study on 35 patients). - Carrier frequency reaches ~1% in northern Sweden due to founder effect.

Environmental/other risk factors: None identified — SLS is purely genetic; there is no described environmental trigger, infectious cause, or acquired risk factor. Preterm birth is a consequence rather than a cause (see Phenotypes below).

Protective factors: None described; missense alleles retaining partial residual FALDH activity are associated with milder phenotypes (genotype-phenotype correlation; JIMD Reports 2020, "the mild end of the phenotypic spectrum," PMC7203653).

Gene-environment interaction: Not established as a feature of this disease; it behaves as a straightforward Mendelian recessive disorder.

3. Phenotypes

Classic triad (onset: infancy/early childhood, essentially universal): - Ichthyosis (HP:0008064): present at birth or within the first year; ranges from erythematous, hyperkeratotic skin to a collodion-membrane presentation; predominantly flexural, sparing central face. Distinctively pruritic — a feature that differentiates SLS from most other congenital ichthyoses (this pruritus is attributed to leukotriene B4 accumulation, see Mechanism). HPO: Ichthyosis (HP:0008064), Hyperkeratosis (HP:0000962), Dry skin (HP:0000958), Erythema (HP:0010783), Pruritus (HP:0000989). - Spastic diplegia/tetraplegia (HP:0001285/HP:0002510): motor milestone delay (sitting, crawling, walking); lower limbs more severely affected than upper; hypertonia, brisk deep tendon reflexes, extensor plantar responses; most patients become wheelchair-dependent by adolescence. Progressive early in life but largely static thereafter. - Intellectual disability (HP:0001249): mild-to-moderate in most; developmental age typically plateaus around 5–6 years; IQ range reported 25–75. Notably "no cognitive deterioration at least during the first three to four decades of life" in most patients (Dove Press review, PMID 32021380 — TACG 2020).

Additional phenotypes: - Glistening white retinal dots / juvenile macular dystrophy / crystalline maculopathy — pathognomonic when present but may not appear until later childhood; often associated with photophobia. HPO: Macular dystrophy (HP:0007754), Retinal pigment epithelial atrophy, Photophobia (HP:0000613), Abnormality of retinal pigmentation (HP:0007703). - Speech abnormality/dysarthria (HP:0001260): pseudobulbar dysarthria, correlating with cognitive level. - Seizures (HP:0001250): affect ~35–40% of patients; usually generalized tonic-clonic; generally controllable with standard antiepileptics; interictal EEG often normal, though nonspecific epileptiform activity is reported in some. - Short stature, skeletal abnormalities (kyphosis, scoliosis), dental enamel abnormality, corneal erosions, microcephaly, hypotonia (axial, in infancy) are variably reported per HPO annotations. - Preterm birth: reported in ~73% of a Dutch cohort (median gestational age 36 weeks), attributed to elevated leukotriene B4 in amniotic fluid/abnormal lipid metabolism (Staps et al., JIMD Reports 2020).

Severity/progression: Broad phenotypic spectrum from severe classic presentations to very mild forms with near-normal intelligence and minor skin/neurologic findings (PMC7203653, "the mild end of the phenotypic spectrum," 2020). Rare neuroregressive courses have been reported in children/adolescents, usually associated with uncontrolled seizures (a "Neurodegenerative Phenotype Associated with SLS," PMC8458237).

Quality of life impact: Chronic pruritus is described as particularly distressing ("agonising pruritus" — Willemsen et al., zileuton trial, PMID 11795678); mobility limitations (wheelchair dependence) and speech impairment materially affect independence; visual impairment from macular dystrophy adds further burden. No validated disease-specific QOL instrument was identified in this search; general pruritus and mobility scales have been used in clinical trials.

4. Genetic/Molecular Information

Causal gene: ALDH3A2 (aldehyde dehydrogenase 3 family member A2; formerly FALDH gene), chromosome 17p11.2, ~31 kb, 11 exons; two transcripts (a 485-aa major isoform from exons 1–10, and a 508-aa FALDHv variant including exon 9′) differing at the C-terminus that anchors the enzyme to the ER/microsomal membrane.

Variant spectrum: >90–100+ unique variants catalogued (LOVD database, ~178 patients compiled): missense/nonsense substitutions, small insertions/deletions, splice-site defects, and complex rearrangements including large deletions (~5% of mutant alleles; ranging from 1–2 nt up to a 1.44-Mb contiguous gene deletion). Most missense variants severely reduce catalytic activity; a subset retain residual activity with altered kinetics/stability, correlating with milder phenotypes.

Founder/recurrent alleles: - c.943C>T (p.Pro315Ser) — Swedish founder mutation, single haplotype. - c.1297_1298delGA (p.Glu433Argfs*3) — common in broader European ancestry patients.

Variant classification: ClinVar contains numerous pathogenic/likely-pathogenic ALDH3A2 entries linked to SLS (e.g., RCV000001709, RCV000001705). ACMG/AMP classification is used clinically; no large gnomAD-based carrier-frequency study was identified in this search beyond the Swedish 1% carrier estimate in Västerbotten.

Functional consequence: Loss-of-function (enzyme deficiency) — no gain-of-function or dominant-negative mechanism described. Both germline alleles must be pathogenic (biallelic); no somatic form exists (this is a congenital metabolic disease, not neoplastic).

Modifier genes: None established; phenotypic variability (including among siblings sharing the same genotype) is documented (PMID 16476818, "Phenotypic variability among adult siblings with SLS") but no specific modifier locus has been identified.

Epigenetics: No disease-specific epigenetic mechanism reported in the literature surveyed.

Chromosomal abnormalities: Not a chromosomal disorder per se, though large contiguous-gene deletions spanning ALDH3A2 and neighboring genes have been reported as a subset of causal alleles.

5. Environmental Information

No environmental toxins, occupational exposures, or lifestyle factors contribute to disease causation — SLS is fully genetically determined. Dietary fat intake modulates symptom severity (see Treatment) rather than causing disease. No infectious trigger is implicated.

6. Mechanism / Pathophysiology

Primary defect: FALDH (fatty aldehyde dehydrogenase, EC 1.2.1.48) normally oxidizes long-chain fatty aldehydes to fatty acids using NAD+. Deficiency causes accumulation of long-chain aliphatic fatty aldehydes and their reduction products, fatty alcohols (higher relative accumulation of octadecanol vs. hexadecanol in plasma).

Causal chain — multiple convergent metabolic disruptions: 1. Fatty alcohol/aldehyde accumulation → covalent adduct formation with cellular macromolecules (proteins, phospholipids) → cytotoxicity. Aldehydes themselves are hard to detect directly because they are highly reactive and rapidly form adducts (e.g., increased N-alkyl-phosphatidylethanolamine as an indirect marker). 2. Ether glycerolipid/plasmalogen metabolism: FALDH normally participates in degrading the alkyl chain cleaved from ether lipids; deficiency disrupts plasmalogen turnover. Plasmalogens comprise 40–50% of myelin phosphatidylethanolamine, linking this pathway to the CNS dysmyelination phenotype (PMC7689726, "Disturbed brain ether lipid metabolism and histology in SLS"). 3. Leukotriene B4 (LTB4) metabolism: FALDH normally oxidizes ω-aldehyde-LTB4 to ω-carboxy-LTB4 (inactivation step). SLS patients show markedly elevated urinary LTB4 and ω-hydroxy-LTB4 with absent ω-carboxy-LTB4 — "the only condition described with profound urinary excretion of LTB4" (Willemsen et al., J Neurol Sci 2001, PMID region cited above). LTB4, a potent chemoattractant/pruritogen, is implicated in both the intractable pruritus and possibly the high rate of preterm birth (elevated amniotic LTB4). 4. Phytol/phytanic acid and isoprenoid alcohol metabolism: FALDH also participates in oxidation of phytol and mevalonate-pathway branched-chain alcohols; deficient in vitro, though these compounds do not accumulate systemically in patients.

Cutaneous pathogenesis: Accumulated fatty aldehydes/alcohols/ether glycerolipids/wax esters in keratinocytes cause abnormal lamellar body formation and secretion in the stratum granulosum (misshapen, granular-content or empty lamellar bodies), impairing epidermal barrier lipid delivery to the stratum corneum → ichthyosis.

Neurological pathogenesis: Neuronal degeneration in cortex and basal ganglia, white-matter demyelination/dysmyelination, and Purkinje cell loss have been reported histopathologically. MRI shows periventricular white-matter T2/FLAIR hyperintensity (frontal/parieto-occipital predominant, cerebellum typically spared) attributed to abnormal myelin maintenance rather than active demyelination. Proton MR spectroscopy reveals a characteristic accumulated-lipid peak at 1.3 ppm (and ~0.8–0.9 ppm), thought to represent accumulated fatty alcohols/metabolites (hexadecanol/octadecanol) — a distinctive, near diagnostic imaging biomarker (AJNR 2004; PMC7056198, "Proton MR Spectroscopy of Sjögren-Larsson's Syndrome").

Mouse model mechanistic insight: Aldh3a2 knockout mice show impaired long-chain-base (sphingolipid precursor) metabolism in neurons, reduced 2-hydroxygalactosylceramide (a myelin-important lipid, via secondary fatty acid 2-hydroxylase inactivation), and behavioral correlates of ataxia/anxiety (light-induced), supporting the CNS lipid-mediated mechanism (PMID 30085884).

Suggested ontology terms: - GO (biological process): fatty aldehyde metabolic process (GO:0033306-adjacent), aldehyde metabolic process (GO:0006081), leukotriene metabolic process (GO:0006691), ether lipid metabolic process, myelination (GO:0042552), keratinocyte differentiation (GO:0030216), lamellar body organization. - GO (cellular component): endoplasmic reticulum membrane (GO:0005789), peroxisome (GO:0005777) — sites of ALDH3A2 localization; lamellar body. - CL: keratinocyte (CL:0000312), oligodendrocyte (CL:0000128), Purkinje cell (CL:0000121), cortical neuron. - CHEBI: hexadecanol, octadecanol, leukotriene B4 (CHEBI:15647), fatty aldehyde.

7. Anatomical Structures Affected

Organ level: Primary — skin (UBERON:0002097) and central nervous system (brain/spinal cord white matter, UBERON:0002240/0002316); secondary — retina/macula (UBERON:0000966), affecting the visual system; skeletal system (kyphoscoliosis, short stature); dental structures (enamel).

Tissue/cell level: Epidermis (stratum granulosum/stratum corneum keratinocytes), cerebral/cerebellar white matter oligodendrocytes and myelin, cortical and basal ganglia neurons, Purkinje cells (cerebellum), retinal pigment epithelium/macula.

Subcellular level: Endoplasmic reticulum/microsomal membrane (FALDH's primary localization) and peroxisome; lamellar bodies (keratinocyte-specific organelle) — GO Cellular Component: ER membrane (GO:0005789), peroxisomal membrane (GO:0005778).

Localization: Skin involvement is generalized but flexural-predominant with facial sparing; CNS white-matter changes are periventricular, frontal/parieto-occipital predominant, bilateral/symmetric (not lateralized); ocular findings are typically bilateral macular.

8. Temporal Development

Onset: Congenital/neonatal for ichthyosis (present at birth or first weeks of life, sometimes as a collodion membrane); spasticity and developmental delay become apparent in infancy (delayed sitting/crawling/walking); macular dystrophy may not be visible until later childhood.

Progression: Skin and motor/spasticity findings are most dynamic in early childhood, then largely static/non-progressive through adulthood — a key distinguishing feature from true neurodegenerative leukodystrophies. Cognitive function is reported stable through the first 3–4 decades in most patients. A minority show an atypical neuroregressive course, usually linked to uncontrolled seizures (PMC8458237; PMC6114270, "Neurodegeneration in an adolescent with SLS: a decade-long follow-up").

Course pattern: Chronic, lifelong, predominantly stable/non-progressive rather than episodic or relapsing-remitting; no spontaneous remission described. Pruritus can fluctuate.

Critical periods: Early diagnosis enabling aggressive physiotherapy is emphasized as improving motor outcome (escholarship.org review, "Importance of early diagnosis and aggressive physiotherapy").

9. Inheritance and Population

Inheritance: Autosomal recessive; complete penetrance for biallelic pathogenic variants; expressivity is variable (documented phenotypic variability even among siblings with identical genotype, PMID 16476818).

Epidemiology: Overall Swedish prevalence ~1 in 250,000 (~0.4/100,000); dramatically higher in Västerbotten, northern Sweden at 8.3 per 100,000 due to a founder effect and historically higher local consanguinity/isolation. Global prevalence elsewhere is not well quantified but the disease is reported worldwide (Europe, Middle East consanguineous families, other regions).

Founder effects/carrier frequency: Carrier frequency up to ~1% in northern Sweden; distinct founder mutations described in different populations (Swedish c.943C>T; broader European c.1297_1298delGA), consistent with multiple independent founder events globally (Journal of Human Genetics 2019 founder-effect study of 35 patients).

Consanguinity: A recognized risk factor in outbred populations outside the Swedish founder cluster (e.g., consanguineous Arab families with multiple affected siblings reported).

Population demographics: No strong sex predilection reported (autosomal recessive, expected ~1:1 M:F). Age distribution reflects a pediatric-onset, lifelong chronic disease with survival into adulthood in most contemporary cohorts.

10. Diagnostics

Laboratory/biochemical tests: - FALDH enzyme activity assay in cultured skin fibroblasts, or fatty alcohol:NAD+ oxidoreductase (FAO) activity — deficient in both, providing a combined diagnostic test. - Urinary biomarkers: elevated LTB4 and ω-hydroxy-LTB4 with absent ω-carboxy-LTB4 — a non-invasive diagnostic approach. - Plasma long-chain fatty alcohol accumulation (octadecanol > hexadecanol).

Imaging: Brain MRI — periventricular white-matter T2/FLAIR hyperintensity; proton MR spectroscopy showing a characteristic 1.3 ppm (and 0.8–0.9 ppm) lipid peak is described as near-diagnostic/definitive in the correct clinical context (MDedge, "Definitive Diagnosis on Magnetic Resonance Spectroscopy"; AJNR 2004).

Ophthalmologic exam: Fundoscopy for glistening white retinal dots (crystalline maculopathy) — pathognomonic when present.

Histopathology: Skin biopsy showing disrupted lamellar body formation/secretion in the stratum granulosum (electron microscopy).

Genetic testing: Sequencing of ALDH3A2 (single-gene test or as part of an ichthyosis/leukodystrophy/spastic-paraplegia gene panel); biallelic pathogenic variants confirm diagnosis. Available via GTR (Genetic Testing Registry) and clinical laboratories (e.g., Myriad Foresight carrier screen lists SLS).

Clinical criteria: Diagnosis is typically made by around age 3 based on the classic triad plus supportive enzyme/biochemical/genetic confirmation; clinical suspicion should arise in any child with ichthyosis plus spastic diplegia/tetraplegia — even with normal intelligence, since the mild end of the spectrum exists.

Differential diagnosis: Cerebral palsy (a common misdiagnosis before ichthyosis is recognized as linked), other congenital ichthyosiform erythrodermas/collodion baby syndromes (non-pruritic, distinguishing feature), other leukodystrophies/hereditary spastic paraplegias, and other neuroichthyotic syndromes (e.g., Refsum disease, trichothiodystrophy — differentiated by lipid/biochemical/genetic profile).

Screening: No population newborn screening program identified; carrier screening is feasible in high-risk populations (e.g., northern Swedish ancestry) and via expanded carrier panels; prenatal/preimplantation testing possible once familial variants are known.

11. Outcome/Prognosis

Survival: Most patients now survive well into adulthood; earlier reports suggested life expectancy roughly halved relative to the general population (historical estimates as low as 15–26 years), but more recent clinical experience is more favorable, especially with modern supportive care.

Disease course/morbidity: Predominantly non-progressive motor/cognitive course after an early developmental period — most patients plateau rather than continuing to decline. Chronic morbidity centers on: wheelchair dependence (progressive spasticity to non-ambulation in many), speech impairment, visual impairment from macular dystrophy, and persistent pruritus/skin discomfort. A minority experience atypical neuroregression, generally associated with poorly controlled seizures.

Complications: Contractures, orthopedic deformities (kyphoscoliosis) from long-standing spasticity, corneal erosions, dental enamel defects, growth/short stature.

Prognostic factors: Genotype (missense variants with residual FALDH activity → milder phenotype); seizure control (uncontrolled seizures associated with neuroregressive courses); early diagnosis and aggressive physiotherapy improving functional motor outcomes.

12. Treatment

Management is currently entirely symptomatic; there is no FDA-approved disease-modifying therapy.

Pharmacotherapy — skin: - Topical emollients/keratolytics: urea creams (2–10%), used 1–2×/day (MAXO:0000004-adjacent topical care; general symptomatic skin care). - Topical vitamin D analogue: calcipotriol, reported to improve ichthyosis. - Systemic retinoids: acitretin — effective for cutaneous symptoms with good tolerability in reported cohorts (short-acting retinoid preferred over older agents like etretinate for pediatric use due to tissue-storage concerns). MAXO/NCIT: Pharmacotherapy (NCIT:C15986) with therapeutic_agent acitretin (CHEBI). - Topical cholesterol/lovastatin (lipid replacement approach) — reported to give slight improvement.

Pharmacotherapy — pruritus/leukotriene pathway: - Zileuton (5-lipoxygenase inhibitor, blocks LTB4/cysteinyl-leukotriene synthesis): open-label trial in 5 patients (3 months) showed significant improvement in pruritus score (P=0.006), general well-being, and EEG background activity (Willemsen et al., Eur J Pediatr 2001, PMID 11795678). However, a subsequent double-blind, placebo-controlled crossover trial in 10 patients did not replicate the pruritus benefit; the authors still recommended a 4–6 week therapeutic trial in patients with severe disabling pruritus (Acta Derm Venereol 2016 zileuton RCT).

Dietary therapy: Fat-restricted diet (~30% of calories from fat) with medium-chain triglyceride (MCT) supplementation and adjusted essential fatty acid (linoleic:linolenic) ratios has been tried, reducing substrate for pathological long-chain fatty alcohol synthesis; results are inconsistent, with occasional cutaneous benefit but no convincing effect on neurologic symptoms — early intervention appeared to help more in reported cases.

Neurological/spasticity management: - Oral baclofen, benzodiazepines, muscle relaxants, anticholinergics. - Intrathecal baclofen — favorable response reported. - Physical/occupational therapy (MAXO:0000011 physical therapy) — emphasized as critical, especially with early diagnosis. - Orthopedic surgery: tendon lengthening, adductor release, dorsal rhizotomy (MAXO:0000004/NCIT:C16186 orthopedic surgical procedure) for contracture/spasticity management.

Seizure management: Standard antiepileptic drugs; seizures are usually controllable.

Experimental/investigational therapies: - ADX-102 (reproxalap) 1% topical cream — an aldehyde-scavenging small molecule tested in the industry-sponsored RESET Trial (NCT03445650), a Phase 3 randomized, double-blind, vehicle-controlled trial (Aldeyra Therapeutics) targeting ichthyosis in SLS; Part 1 enrolled 11 subjects (2018–2020). A related compound, ADX-629, has also been studied (NCT05443685). - Aldehyde scavenger NS2 — reduces N-alkyl-phosphatidylethanolamine formation in FALDH-deficient CHO cells and mouse models; early-phase clinical development noted. - PPAR-α agonist bezafibrate — increased ALDH3A2 expression and residual enzyme activity in fibroblasts from missense-mutation patients in vitro; not yet clinically trialed. - ALDH activator Alda-89 — stimulates residual FALDH activity ~3-fold in vitro; no clinical trials yet. - JNK pathway inhibitors — rationale based on trans-2-hexadecenal-induced JNK activation/apoptosis in model systems. - Gene therapy: rAAV-2-mediated FALDH gene transfer restored ~15-fold FALDH activity (60–70% of normal) in transduced SLS keratinocytes in vitro, with 84% of cells regaining resistance to long-chain aldehyde toxicity; lentiviral hematopoietic stem cell gene therapy has been tested in mouse models. Clinical translation remains preliminary; transgenic mouse overexpression models have been hampered by neonatal lethality.

Natural history study: NCT01971957 ("Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers") — ongoing NIH-affiliated natural history study informing future trial design.

13. Prevention

Primary prevention: Not applicable in the traditional sense (no environmental exposure to avoid); genetic counseling is the principal primary-prevention tool for at-risk couples (both carriers), especially in high-prevalence founder populations (northern Sweden) or consanguineous unions.

Secondary prevention/screening: Carrier screening in high-risk populations (feasible via targeted panels, e.g., commercial expanded carrier screens); prenatal diagnosis and preimplantation genetic diagnosis (PGD) are technically available once familial ALDH3A2 variants are identified, though no population-wide newborn screening program was identified in this search.

Tertiary prevention: Early clinical diagnosis (target by ~age 3) paired with aggressive physiotherapy is repeatedly emphasized in the literature as improving functional motor outcomes and preventing/minimizing contractures; regular ophthalmologic surveillance for macular dystrophy and dental/orthopedic follow-up to manage secondary complications.

Genetic counseling: Standard autosomal-recessive recurrence-risk counseling (25% recurrence per pregnancy for carrier couples); relevant in populations with known founder mutations or consanguinity.

14. Other Species / Natural Disease

No naturally occurring veterinary/companion-animal form of SLS (spontaneous ALDH3A2 deficiency) was identified in this search — this appears to be a human-specific reported condition without an OMIA veterinary entry found. The relevant cross-species information is limited to engineered model organisms (see below) rather than natural disease in other species.

Orthologous gene: Aldh3a2 (mouse; NCBI Gene ortholog) — used to generate the knockout model discussed below.

15. Model Organisms

Mouse model (Aldh3a2 knockout, mammalian genetic model): - Aldh3a2 KO mice show impaired long-chain-base (sphingolipid precursor) metabolism in neurons and reduced 2-hydroxygalactosylceramide (a myelin-relevant lipid, via secondary fatty acid 2-hydroxylase inactivation) in brain tissue. - Behavioral phenotype recapitulation: increased paw slips on balance-beam testing (motor/coordination deficit) and light-induced anxiety (potentially modeling photophobia), corresponding to some human SLS features (PMID 30085884). - Limitations: Transgenic/overexpression mouse models attempting to model the disease more fully have suffered neonatal lethality, limiting some in vivo therapeutic testing; the KO model does not fully recapitulate the ichthyosis or spasticity phenotype seen in humans, so it is used primarily for CNS lipid/mechanistic studies rather than full disease modeling.

Cellular models: - Patient-derived dermal fibroblasts and keratinocytes — standard for FALDH/FAO enzyme activity assays and gene-therapy vector testing (rAAV-2 FALDH transduction studies). - iPSC-derived oligodendrocyte-lineage cells from SLS patients — recently established to study accumulation of ether phospholipids and CNS-relevant lipid pathology in a human cellular system (PMC11608845, 2024). - CHO (Chinese hamster ovary) cell lines engineered to be FALDH-deficient — used for aldehyde-scavenger (NS2) and gene-transfer proof-of-concept studies.

Applications: These models collectively support study of (1) keratinocyte lamellar body/lipid barrier dysfunction, (2) CNS myelin lipid abnormalities, and (3) therapeutic strategies (gene transfer, aldehyde scavenging, enzyme activators) prior to human trials.

Summary Table of Key Ontology Term Suggestions

Category Suggested terms
Disease MONDO:0010031; OMIM:270200; ORPHA:816; DOID:14501
Gene HGNC:403 ALDH3A2; OMIM:609523
Phenotype (HP) HP:0008064 Ichthyosis; HP:0001285 Spastic tetraplegia; HP:0002510 Spastic diplegia; HP:0001249 Intellectual disability; HP:0007754 Macular dystrophy; HP:0000613 Photophobia; HP:0000989 Pruritus; HP:0001250 Seizure; HP:0001260 Dysarthria
GO (process) Aldehyde metabolic process; leukotriene metabolic process; ether lipid metabolic process; myelination; keratinocyte differentiation
GO (component) Endoplasmic reticulum membrane (GO:0005789); peroxisome (GO:0005777)
CL Keratinocyte (CL:0000312); oligodendrocyte (CL:0000128); Purkinje cell (CL:0000121)
UBERON Skin epidermis; white matter of CNS; macula
CHEBI Leukotriene B4; hexadecanol; octadecanol
MAXO Physical therapy (MAXO:0000011); surgical procedure (MAXO:0000004)

Sources: